3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
4
Gynecologic
2
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
HER2-mutant Non-Small Cell Lung Cancer
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
39
Gemcitabine
30
Nivolumab
15
Cetuximab
13
Carboplatin
13
Cyclophosphamide
12
Cisplatin
12
Irinotecan
10
Docetaxel
10
130-nm albumin-bound paclitaxel
10
Trastuzumab
8
Magnetic Resonance Spectroscopy
8
fludarabine
7
aldesleukin
7
Paclitaxel
7
Drug Therapy
7
Bevacizumab
7
Taxes
6
Specimen Handling
6
Fluorouracil
6
Capecitabine
6
Albumin-Bound Paclitaxel
6
sargramostim
5
Pemetrexed
5
Oxaliplatin
5
Ipilimumab
5
spartalizumab
4
durvalumab
4
Standard of Care
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
trastuzumab deruxtecan
×
Thoracic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled